Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Date publication

avril 2025

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HENNEQUIN Audrey

Tous les auteurs :
Llombart-Cussac A, Harper-Wynne C, Perelló A, Hennequin A, Fernández-Ortega A, Colleoni M, Marín S, Quiroga V, Medioni J, Iranzo V, Wheatley D, Del Barco Berrón S, Antón A, Dobi E, Ruiz-Borrego M, Alcalá-López D, Pérez-Escuredo J, Antonarelli G, Sampayo-Cordero M, Pérez-García JM, Cortés J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40294349

Résumé

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC). However, there is no definitive consensus on the preferred second-line treatment option. The PALMIRA trial investigated whether palbociclib rechallenge with an alternative ET would improve the antitumor activity in patients progressing after a first-line palbociclib-containing regimen.

Référence

J Clin Oncol. 2025 04 28;:JCO2401865